Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$3.29 - $6.64 $987,000 - $1.99 Million
300,000 Added 13.04%
2,600,000 $16.1 Million
Q3 2023

Nov 14, 2023

BUY
$3.3 - $4.83 $7.59 Million - $11.1 Million
2,300,000 New
2,300,000 $9.38 Million
Q1 2023

May 15, 2023

BUY
$2.68 - $4.79 $1.07 Million - $1.92 Million
400,000 Added 24.24%
2,050,000 $9.82 Million
Q4 2022

Feb 14, 2023

SELL
$1.22 - $2.85 $2.87 Million - $6.7 Million
-2,350,000 Reduced 58.75%
1,650,000 $4.7 Million
Q3 2022

Nov 14, 2022

BUY
$0.59 - $1.44 $2.36 Million - $5.76 Million
4,000,000 New
4,000,000 $4.76 Million
Q3 2021

Nov 15, 2021

SELL
$1.27 - $8.17 $1.91 Million - $12.3 Million
-1,500,000 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$6.55 - $8.98 $18 Million - $24.7 Million
-2,754,892 Reduced 64.75%
1,500,000 $11.4 Million
Q1 2021

May 17, 2021

SELL
$6.1 - $7.69 $4.55 Million - $5.73 Million
-745,108 Reduced 14.9%
4,254,892 $28.2 Million
Q2 2020

Aug 14, 2020

SELL
$5.37 - $8.11 $1.42 Million - $2.14 Million
-263,685 Reduced 5.01%
5,000,000 $34.6 Million
Q1 2020

May 15, 2020

SELL
$4.35 - $8.79 $1.89 Million - $3.82 Million
-434,657 Reduced 7.63%
5,263,685 $29.9 Million
Q4 2019

Feb 14, 2020

BUY
$4.23 - $8.29 $7.18 Million - $14.1 Million
1,698,342 Added 42.46%
5,698,342 $42.8 Million
Q4 2018

Feb 14, 2019

BUY
$1.66 - $4.16 $830,000 - $2.08 Million
500,000 Added 14.29%
4,000,000 $7.16 Million
Q3 2018

Nov 14, 2018

BUY
$3.75 - $4.65 $1.88 Million - $2.33 Million
500,000 Added 16.67%
3,500,000 $15.2 Million
Q2 2018

Aug 14, 2018

BUY
$3.7 - $5.8 $11.1 Million - $17.4 Million
3,000,000 New
3,000,000 $11.1 Million

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $815M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.